Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study - Wikidata - awgldk - TriplyDB

Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study

Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study

http://www.wikidata.org/entity/Q33382930

about

Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?The evolution of systemic therapy in sarcoma.Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets.Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.Small-molecule inhibitors of the PI3K signaling network Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study.Camptothecin-based regimens for treatment of ewing sarcoma: past studies and future directions Pharmacologic management of high-risk neuroblastoma in children Targeting the DNA repair pathway in Ewing sarcoma A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy.Molecular profiling of childhood cancer: Biomarkers and novel therapies Targeted therapy in cancer.Ten challenges in the management of neuroblastoma.Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature.A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.Recent advances in oral anticancer agents for colon cancer.Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment Clinical research on rare diseases of children: neuroblastoma.Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition.Omega-3 fatty acid supplementation delays the progression of neuroblastoma in vivo.Inhibition of SN-38 glucuronidation by gefitinib and its metabolite.Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography for Follow-Up of 13-cis-Retinoic Acid Treatment for Residual Neuroblastoma After Myeloablative Chemotherapy.5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma.Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma.Novel natural withanolides induce apoptosis and inhibit migration of neuroblastoma cells through down regulation of N-myc and suppression of Akt/mTOR/NF-κB activation.Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.

P2860

Q26795742-035690D5-96B6-4120-8B99-D005E4F7BB45 Q33274710-3E1719BF-C999-4D5A-9F3E-63E982AAE80C Q33387707-1CD952BC-9E7D-4635-AC6C-10C3F69220F3 Q33392673-316FD256-8510-4EC2-8841-2DBD9D5E3784 Q33402525-E223E7CA-0418-4D61-8E0B-3F6472213F63 Q33430055-9D830BFC-3D17-4B5D-8FBE-5BF65FABC113 Q33441292-48B91EFC-5A76-497D-B075-3B2CD54E7BAB Q33883982-88F271FA-A2CB-437F-9C87-26357B31F3CB Q34344177-2B2EC765-5C89-4618-9E1C-BE9FBC501FD8 Q34571940-BA6EB226-C9E9-479F-A46C-5FCFAB65155B Q34632966-4BCD236A-3FCA-4151-BFD9-B92571088D90 Q34679179-CB7EE7CC-7B00-4440-9CA9-C1E43F77F838 Q34787772-CEC46C3E-25E8-49C9-BFFB-6273E66A12D9 Q35064095-3240FB5D-582F-4B02-94F9-45C1648E2F41 Q35283099-E3121473-8449-4EC5-B29E-6BFC0408F474 Q35597039-DE62FD84-1B1A-4A88-B226-670336A85E34 Q35667216-F6DB4BE1-4386-4C0E-84AA-F5948AB78309 Q36114222-AB4CF707-CD11-4201-B9C0-38FC4D275BA5 Q36250783-B315EFEF-9D1D-4356-9A87-4F0F7243DD0E Q37204270-37C7B40E-590C-454F-BC5C-B8023563928F Q38029366-5FC0552A-D42F-4D77-844B-09004C64F803 Q38041019-1DABCA23-A750-4D59-B74A-D3FB4FC54C25 Q38086448-767AA9F0-6B5D-4FFF-96BD-783651470565 Q38167885-DBCA0541-42AB-4C2C-906A-A7275661F0AC Q38262500-A0404FAD-F4AE-46E1-9938-C70E42C7FFE0 Q38791761-C50286C9-F1F0-42B3-8B8C-E154343C0D6D Q38909208-298BE822-069D-47A6-9397-10E9B2DE132B Q38961012-AADA53E1-703B-435B-9B2E-0CDE259AA35D Q39285494-FFC81E14-DAA1-4DCB-AD1C-2500AA0BB20B Q39700720-A033FDC0-1D15-4F6B-B753-AB385BA9CD5F Q41008169-2F6311A2-4972-4519-8891-7F0497DD321A Q43205419-77C0B5DB-F068-4675-94AB-D8344B4DD978 Q44260246-0AFA65BA-B60B-4D7E-B5FA-316805CD2184 Q44523074-2752D5A7-6C19-45EF-A5C2-DEA32D214EE7 Q51734229-2D7BD7ED-3775-4D87-9CDE-F62A74325B67 Q54442312-3054BE70-9F2D-4748-9AB2-AF7C5D4818E8

P2860

Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study

http://www.wikidata.org/entity/Q33382930

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Phase I trial of oral irinotec ...... stoma therapy consortium study

@ast

Phase I trial of oral irinotec ...... stoma therapy consortium study

@en

type

label

Phase I trial of oral irinotec ...... stoma therapy consortium study

@ast

Phase I trial of oral irinotec ...... stoma therapy consortium study

@en

prefLabel

Phase I trial of oral irinotec ...... stoma therapy consortium study

@ast

Phase I trial of oral irinotec ...... stoma therapy consortium study

@en

P1433

Q33382930-ED08F073-2E86-48DE-A8DA-CF35676FBBB6

P1476

Q33382930-A02021DA-0831-4D2E-909E-BE5DCF031C30

P2093

Q33382930-4111B5CB-EFB7-4623-8AAC-B43F77C722D6

Q33382930-70799715-E181-43F7-9B49-DF3E38FE7590

Q33382930-90136505-7002-4045-8ED8-B51EEF51B974

Q33382930-9C9BFD29-7719-4554-B746-C09BE32B938E

Q33382930-AFE482FE-C26E-4109-B142-7090CE1C3BA0

Q33382930-B0ABEF2E-FBC3-4350-AF6C-0536CA95C2E2

Q33382930-E95C43B3-5D2E-4136-BDF2-D1839234CAA1

Q33382930-EF081CD6-52D1-48BC-9374-CFC7F754DAA7

Q33382930-F17A3C87-2EA0-465C-BD3B-145761D93CD2

Q33382930-FB0EEDC0-E04C-4635-806D-800354AB0B88

P2860

Q33382930-10D5C513-78C3-4B0D-BE9E-EB78066BE281

Q33382930-186DDC02-A86C-4DE8-9A28-D1DB1302CBB7

Q33382930-1E3B93EF-27B6-4819-92D9-6F4F236C28B8

Q33382930-208D4D7E-AE3F-4F07-B9DA-981D90027D76

Q33382930-2597C843-643E-401D-AC55-3D86ADDC671B

Q33382930-304AEFBA-F4E6-4CC4-A2CC-AB573B2356F7

Q33382930-3088200C-4B3E-4096-BDA0-B7F57D386A64

Q33382930-3B665233-B78D-418C-B3B1-684487F7CE50

Q33382930-3C2E13E3-4ED1-4F0F-AF09-36DD741C0EF4

Q33382930-47B0720E-E353-435F-A172-961948E81E80

P304

Q33382930-E101F4CB-18E5-46C4-BCAF-2A7571C2F3A9

P31

Q33382930-A8C57629-8079-4FB6-B0CE-FE659580C8B2

P356

Q33382930-BC922623-FA0C-4700-837C-7ED8F0CD0BCB

P407

Q33382930-FC16448A-A3F6-43B1-92EA-23C9128AAD10

P433

Q33382930-EC2EA340-9256-4531-B116-67DE2C2E3FFF

P478

Q33382930-3D72B4A5-F0BB-438C-800B-71C4F673A497

P50

Q33382930-36DEBB1A-2242-44D1-9AAB-D236BB084B76

Q33382930-CF71BEBD-966A-40A5-9DF0-40CF87AD6E55

P577

Q33382930-8D1DA611-BEB8-4B03-BC7B-AFD84B38D6DD

P698

Q33382930-D4D4A7FE-8389-4456-B712-ADA1C7DCF30F

P921

Q33382930-A9FF0096-100E-4B35-AB7D-F907663AA0C3

P932

Q33382930-535A83D4-6D87-4175-AA67-7596EFACE9ED

P356

JCO.2008.18.5918

P1433

Journal of Clinical Oncology

P1476

Phase I trial of oral irinotec ...... stoma therapy consortium study

@en

P2093

Clinton F Stewart

http://www.w3.org/2001/XMLSchema#string

Hollie A Jackson

http://www.w3.org/2001/XMLSchema#string

John M Maris

http://www.w3.org/2001/XMLSchema#string

Judith G Villablanca

http://www.w3.org/2001/XMLSchema#string

Julie R Park

http://www.w3.org/2001/XMLSchema#string

Katherine K Matthay

http://www.w3.org/2001/XMLSchema#string

Kristine R Crews

http://www.w3.org/2001/XMLSchema#string

Lars M Wagner

http://www.w3.org/2001/XMLSchema#string

Randall A Hawkins

http://www.w3.org/2001/XMLSchema#string

Susan Groshen

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine.

A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.

Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.

Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.

Role of pharmacogenetics in irinotecan therapy.

A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours.

Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Société Française des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study.

Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group.

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

P304

1290-1296

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.18.5918

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Heike E Daldrup-Link

P577

2009-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19171709

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

2667827

http://www.w3.org/2001/XMLSchema#string